Merida Biosciences, Inc.

Merida Biosciences is a biotechnology company focused on developing innovative therapies for autoimmune and allergic disorders through a proprietary therapeutic platform. Founded in 2022 and based in Cambridge, US, Merida Biosciences specializes in precision therapies for antibody-driven diseases. The company has successfully completed 1 deal to date, with its most recent funding round occurring on April 8, 2025. The firm raised USD 121.

00 mn in a Series A funding round co-led by BVF Partners, Bain Capital, GV, Perceptive Advisors, and Third Rock Ventures. The founder's history is currently not available. Merida Biosciences specializes in the development of innovative therapies targeting autoimmune and allergic disorders through its proprietary platform. The company’s core product offerings focus on precision therapies designed to eliminate pathogenic drivers of antibody-driven diseases, providing targeted intervention that addresses the root causes of conditions rather than merely alleviating symptoms.

These therapies aim to improve patient outcomes by delivering greater efficacy with a reduced risk of serious side effects. The company is actively engaging with healthcare providers and biotechnology partners across North America and Europe, targeting markets where the prevalence of autoimmune diseases is significant. End users primarily include patients suffering from chronic autoimmune conditions, as well as healthcare professionals involved in the treatment and management of these disorders. Merida Biosciences generates revenue through a combination of partnerships and direct sales of its therapeutic products, emphasizing collaborative relationships with healthcare institutions and biopharmaceutical companies.

The transaction structure typically involves establishing partnerships that may include milestone-based payments and royalties on sales, particularly as products progress through clinical development and receive regulatory approval. The company’s flagship products are positioned for significant market entry following successful clinical trials, with pricing strategies aligned to competitive market standards within the biotechnology sector. These financial agreements and product sales are structured to ensure sustainable revenue growth while fostering ongoing collaboration with key stakeholders in the healthcare ecosystem. In April 2025, Merida Biosciences, Inc.

raised USD 121. 00 mn in Series A funding to support the development of therapeutics for multiple autoimmune and allergic diseases. The company plans to leverage this funding to expand its product pipeline and enhance its therapeutic offerings. Specific upcoming products are currently underway, with strategic plans for entering new markets across North America and Europe.

The funding will facilitate these initiatives as Merida focuses on advancing its clinical trials and solidifying partnerships within the healthcare landscape.